TIDMMDC
RNS Number : 9458A
Mediclinic International plc
07 June 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
("Mediclinic", the "Company", or the "Group")
7 June 2021
NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out the details of awards over ordinary
shares in Mediclinic ("Shares") granted to directors and other
persons discharging managerial responsibilities ("PDMRs") on 4 June
2021 under the Company's short-term incentive scheme (the "STI")
and long-term incentive plan (the "LTIP").
Awards granted under the Company's STI and LTIP
On 4 June 2021, awards over Shares were granted to the following
directors and other PDMRs under the Company's STI and LTIP, in
accordance with the remuneration policy approved by shareholders in
July 2020 (the "Remuneration Policy"):
Name Director/ Number of Shares Number of Shares
PDMR awarded under awarded under
the FY21 STI the LTIP
Dr Carel Aron van der
Merwe Director 122 614 356 181
----------- ----------------- -----------------
Petrus Jurgens Myburgh Director 80 655 190 569
----------- ----------------- -----------------
David John Hadley PDMR n/a 122 259
----------- ----------------- -----------------
Gert Cornelis Hattingh PDMR n/a 72 993
----------- ----------------- -----------------
Dr Dirk Cornelius le
Roux PDMR n/a 57 158
----------- ----------------- -----------------
Dr Daniel Liedtke PDMR n/a 118 270
----------- ----------------- -----------------
Magnus Oetiker PDMR n/a 96 910
----------- ----------------- -----------------
Koert Hendrik Stefanus
Pretorius PDMR n/a 76 408
----------- ----------------- -----------------
Dr René Toua PDMR n/a 59 487
----------- ----------------- -----------------
Dr Tyson Bruno Welzel PDMR n/a 47 688
----------- ----------------- -----------------
Awards under the STI and LTIP were granted for nil consideration
and are based on the average of the middle-market quotations of a
Share during a period of five dealing days ending with the dealing
day before the day of grant, which equates to GBP3.35 per
Share.
STI awards
The Remuneration Committee (the "Committee") considered at
length the pay-out under the STI to the executive directors in
respect of the financial year ended 31 March 2021 ("FY21"), taking
into account financial and overall business performance and the
experience of shareholders, employees and clients.
The performance delivered against the pre-defined adjusted EBIT
target resulted in a pay-out of 100% of a maximum bonus.
The Committee reviewed the clinical quality, client experience
and employee engagement performance for the Group and considered
that the formulaic outcome was an appropriate reflection of the
Group's overall performance, and the performance and leadership by
the executives of the business through COVID-19. However, the
Committee was acutely aware that the dividend was likely to remain
suspended as part of the Group's broad response to maintaining its
liquidity position, and as such, determined that it would be
appropriate for the release of the STI to be conditional on the
Company's dividend being reinstated. The payment of the cash
proportion of the FY21 STI (50%) was therefore deferred until such
time. The remaining 50% of the bonus award was deferred into
shares, with the awards subject to the reinstatement of the
Company's dividend as well as the usual two-year vesting period and
continued employment condition under the Remuneration Policy.
Further details on the Committee's decision regarding the FY21
STI are set out in the Remuneration Committee Report included in
the Group's Annual Report and Financial Statements for the year
ended 31 March 2021 (the "FY21 Annual Report"), which will be
published towards the end of June 2021.
LTIP awards
On 4 June 2021, the Committee also granted awards under the
Company's LTIP to the Group Chief Executive Office and Group Chief
Financial Officer with a face value equivalent to 200% and 150% of
salary, respectively (the "FY22 LTIP Awards"). The Committee
considered it appropriate to grant awards in line with the normal
maximum levels under the Remuneration Policy taking into account
share price performance since the grant of FY21 LTIP Awards and the
level of stretch included in the performance targets. Awards were
also granted to the other members of the Group Executive Committee.
The Committee will also use its discretion to amend the vesting
outcome where it considers that it is not representative of
business performance. This includes consideration of any potential
'windfall gains' at the point of vesting.
Awards granted under the LTIP are structured as conditional
awards, with vesting being subject to the satisfaction of
performance conditions over a three-year period. Awards granted to
the executive directors will be settled in shares upon vesting, and
will be subject to a further two-year holding period.
Details of the performance conditions for the FY22 LTIP Awards
are set out in the Remuneration Committee Report included in the
Group's FY21 Annual Report.
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Dr Carel Aron van der Merwe
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Executive Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4.1 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Short-Term Incentive
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 122 614
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
122 614
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
4.2 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 356 181
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
356 181
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Petrus Jurgens Myburgh
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Financial Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4.1 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Short-Term Incentive
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 80 655
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
80 655
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
4.2 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 190 569
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
190 569
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name David John Hadley
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Chief Executive Officer - Mediclinic Middle
East
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 122 259
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
122 259
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Gert Cornelis Hattingh
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Governance Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 72 993
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
72 993
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Dr Dirk Cornelius le Roux
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Information Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 57 158
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
57 158
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Dr Daniel Liedtke
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Chief Executive Officer: Hirslanden
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 118 270
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
118 270
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Magnus Oetiker
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Strategy and Human Resources
Officer - Mediclinic International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 96 910
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
96 910
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Koert Hendrik Stefanus Pretorius
----------------------- ----------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position / status Chief Executive Officer - Mediclinic Southern
Africa
----------------------- ----------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ----------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ----------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ----------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ----------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 76 408
----------
----------------------- ----------------------------------------------
d) Aggregated information
Aggregated volume
Price
76 408
GBPnil
----------------------- ----------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ----------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ----------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Dr René Toua
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Clinical Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 59 487
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
59 487
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
1. Details of PDMR / person closely associated with them
("PCA")
a) Name Dr Tyson Bruno Welzel
----------------------- ---------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------
a) Position / status Group Chief Innovation Officer - Mediclinic
International plc
----------------------- ---------------------------------------------
b) Initial notification Initial Notification
/ amendment
----------------------- ---------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Mediclinic International plc
----------------------- ---------------------------------------------
b) LEI 2138002S5BSBIZTD5I60
----------------------- ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description Ordinary Shares
of the financial
instrument GB00B8HX8Z88
Identification
Code
----------------------- ---------------------------------------------
b) Nature of the Award over ordinary shares in Mediclinic
transaction International plc granted at nil cost under
the Company's Long-Term Incentive Plan
----------------------- ---------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) GBPnil 47 688
----------
----------------------- ---------------------------------------------
d) Aggregated information
Aggregated volume
Price
47 688
GBPnil
----------------------- ---------------------------------------------
e) Date of the 4 June 2021
transaction
----------------------- ---------------------------------------------
f) Place of the Outside a trading venue
transaction
----------------------- ---------------------------------------------
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five
subacute hospitals, two mental health facilities, 18 day case
clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals
and four day case clinics in Switzerland with more than 1 900
inpatient beds; Mediclinic Southern Africa operations included 50
hospitals (three of which in Namibia), five sub-acute hospitals,
two mental health facilities and 12 day case clinics (four of which
operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 18 outpatient clinics with more
than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu
Dhabi and will open a 200-bed hospital in the Kingdom of Saudi
Arabia in mid-2022.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address : 6(th) Floor, 65 Gresham Street, London,
EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom) : Morgan Stanley & Co
International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLGDLDUGDGBS
(END) Dow Jones Newswires
June 07, 2021 05:00 ET (09:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024